Progress and Challenges in Implementing the Research on ESKAPE Pathogens

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are responsible for a substantial percentage of nosocomial infections in the modern hospital and represent the vast majority of isolates whose resistance to antimicrobial agents presents serious therapeutic dilemmas for physicians. Over the years, improved molecular biology techniques have led to detailed information about individual resistance mechanisms in all these pathogens. However, there remains a lack of compelling data on the interplay between resistance mechanisms and between the bacteria themselves. In addition, data on the impact of clinical interventions to decrease the prevalence of resistance are also lacking. The difficulty in identifying novel antimicrobial agents with reliable activity against these pathogens argues for an augmentation of research in the basic and population science of resistance, as well as careful studies to identify optimal strategies for infection control and antimicrobial use.

[1]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[2]  H. Chambers Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications , 1997, Clinical microbiology reviews.

[3]  L. Rice,et al.  Role of Class A Penicillin-Binding Proteins in the Expression of β-Lactam Resistance in Enterococcus faecium , 2009, Journal of Bacteriology.

[4]  S. Mobashery,et al.  β-Lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome , 2005, Cellular and Molecular Life Sciences.

[5]  S. Normark,et al.  Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta‐lactamase induction. , 1994, The EMBO journal.

[6]  A. Robicsek,et al.  Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat , 2009, Clinical Microbiology Reviews.

[7]  K. Lewis Multidrug tolerance of biofilms and persister cells. , 2008, Current topics in microbiology and immunology.

[8]  M. Arthur,et al.  Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147 , 1993, Journal of bacteriology.

[9]  P. Pronovost,et al.  An intervention to decrease catheter-related bloodstream infections in the ICU. , 2006, The New England journal of medicine.

[10]  L. Rice,et al.  Genetic Linkage and Cotransfer of a Novel,vanB-Containing Transposon (Tn5382) and a Low-Affinity Penicillin-Binding Protein 5 Gene in a Clinical Vancomycin-Resistant Enterococcus faecium Isolate , 1998, Journal of bacteriology.

[11]  J. Pitout Multiresistant Enterobacteriaceae: new threat of an old problem , 2008, Expert review of anti-infective therapy.

[12]  J. Whitecar,et al.  Pseudomonas Bacteremia in Patients with Malignant Diseases , 1970, The American journal of the medical sciences.

[13]  J. Weissenbach,et al.  Comparative Genomics of Multidrug Resistance in Acinetobacter baumannii , 2006, PLoS genetics.

[14]  N. Hanson,et al.  Role of ampD Homologs in Overproduction of AmpC in Clinical Isolates of Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[15]  J. Frère,et al.  AmpD, essential for both β‐lactamase regulation and cell wall recycling, is a novel cytosolic N‐acetylmuramyl‐L‐alanine amidase , 1995, Molecular microbiology.

[16]  R A Weinstein,et al.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. , 1996, The Journal of infectious diseases.

[17]  L. Martínez-Martínez,et al.  Porin expression in clinical isolates of Klebsiella pneumoniae. , 1999, Microbiology.

[18]  V. Tam,et al.  Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of Pseudomonas aeruginosa , 2010, Antimicrobial Agents and Chemotherapy.

[19]  J. Frère,et al.  Cytosolic Intermediates for Cell Wall Biosynthesis and Degradation Control Inducible β-Lactam Resistance in Gram-Negative Bacteria , 1997, Cell.

[20]  Grace Yim,et al.  Antibiotics as signalling molecules , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.

[21]  L. Rice,et al.  The KQ Element, a Complex Genetic Region Conferring Transferable Resistance to Carbapenems, Aminoglycosides, and Fluoroquinolones in Klebsiella pneumoniae , 2008, Antimicrobial Agents and Chemotherapy.

[22]  T. Pruett Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .

[23]  L. Rice Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. , 2008, The Journal of infectious diseases.

[24]  P. Caspers,et al.  Impact of Specific pbp5 Mutations on Expression of β-Lactam Resistance in Enterococcus faecium , 2004, Antimicrobial Agents and Chemotherapy.

[25]  H. Nikaido Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.

[26]  I. Brook The role of beta-lactamase-producing-bacteria in mixed infections , 2009, BMC infectious diseases.

[27]  D. Livermore Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.

[28]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[29]  S. Projan,et al.  Antibacterial drug discovery: is it all downhill from here? , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[31]  R. Goering,et al.  In vitro antagonism of beta-lactam antibiotics by cefoxitin , 1982, Antimicrobial Agents and Chemotherapy.